First ever longtudinal study from ALS non-profit focuses on finding digital biomarkers using IBM Research’s proprietary AI. The study leverages audiovisual samples from participants with ALS, genetic carriers, and caregivers.
ALS genetic carrier finds value in EverythingALS study leveraging digital biomarkers as a means to create tools for early detection of ALS and potentially other neurological diseases.
The biotechnology company has reported its candidate for treating amyotrophic lateral sclerosis patients has shown promising results in an early-phase study.
The pharma company has completed enrollment of amyotrophic lateral sclerosis patients in its study investigating drugs like verdiperstat, an oral treatment.
Project ALS has selected Medidata’s biomarker discovery solution for its research projects, aiming to improve understanding of the ALS disease process and develop new therapeutic strategies.
